Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Prifetrastat
prifetrastat Reference · 1 trial · 1 indication
AUCinf was area under the plasma concentration time-curve from zero (pre-dose) extrapolated out to infinite time (If data permits).
Cmax was the maximum observed plasma concentration directly observed from data.
AUCinf was area under the plasma concentration time-curve from zero (pre-dose) extrapolated out to infinite time (If data permits).
Cmax was the maximum observed plasma concentration directly observed from data.
AUCinf was area under the plasma concentration time-curve from zero (pre-dose) extrapolated out to infinite time (If data permits).
Cmax was the maximum observed plasma concentration directly observed from data.
| Arm | Type | Description |
|---|---|---|
| Arm 1 prifetrastat | ACTIVE_COMPARATOR | Crossover |
| Arm 2 prifetrastat | ACTIVE_COMPARATOR | Crossover |
| Name | Type | Description |
|---|---|---|
| prifetrastat Reference | DRUG | Reference Treatment |
| prifetrastat Test 1 | DRUG | Test 1 Treatment |
| prifetrastat Test 2 | DRUG | Test 2 Treatment |
Inclusion * Females of non-childbearing potential and males \>=18 years of age at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs and 12-lead ECGs. * BMI of 18-32 kilogram per meter square(Kg/m\^2);...
Prifetrastat is an investigational small molecule being studied in healthy adults and healthy participants. It is not approved for any disease and is currently in Phase 1 clinical development. The ongoing trials are designed to learn how different forms of the study medicine are taken up into the blood and how food affects its uptake.
Prifetrastat is a small molecule with a target class described as a -stat enzyme inhibitor. The specific molecular target is not disclosed in the available information. It is being studied in healthy participants to understand its pharmacokinetics, or how the drug is absorbed into the blood.
Prifetrastat is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company is conducting Phase 1 clinical trials to evaluate how the drug is taken up into the blood in healthy adults.
Prifetrastat is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials are listed, one recruiting and one not yet recruiting, both enrolling healthy adult participants.
Prifetrastat is being studied in two Phase 1 trials. NCT07721402 is a study in Belgium enrolling 32 healthy participants to learn how different forms of the medicine are taken up into the blood. NCT07731100 is a study in the United States enrolling 12 healthy adults to evaluate how food affects drug uptake.
Prifetrastat is also known as prifetrastat in combination with fulvestrant and prifetrastat Reference. The available clinical trials, however, study prifetrastat alone in healthy participants and do not include fulvestrant or any combination therapy.